US › Healthcare

InflaRx N.V. (IFRX)

US · Healthcare · Biotechnology

$1.30-3.69%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-10.6M

EPS

$-0.11

EPS estimate

$-0.08

EPS came in at -0.11 against a street estimate of -0.08 — a miss of 37.5%.

Key statistics

Market cap

$238.7M

Forward P/E

0.0

P/B

1.59

Book value

$1.11

EPS (TTM)

$-0.58

52-week high

$2.95

52-week low

$0.80

50-day MA

$1.85

200-day MA

$1.64

Beta

2.42

Analyst view

Analysts rate InflaRx N.V. a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $8.29.

Shareholding

Insiders

2.96%

Institutions

70.46%

Largest institutional holders

Fund	Stake
Suvretta Capital Management, LLC	15.56%
TCG Crossover Management, LLC	9.84%
FMR Inc	5.54%
COMMODORE CAPITAL LP	4.95%
Kalehua Capital Management LLC	3.93%
Spruce Street Capital LP	3.63%
Farallon Capital Management, L.L.C.	2.26%
StemPoint Capital LP	2.19%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for InflaRx N.V. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.